MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$88,000,000
Proceeds from exercise of
stock options
$1,103,940
Proceeds from employee
stock purchase plan
$19,616
Net cash provided by
(used in) investing...
$47,736,288
Net cash provided by
(used in) financing...
$1,123,556
Canceled cashflow
$40,263,712
Net increase
(decrease) in cash and cash...
$15,514,162
Canceled cashflow
$33,345,682
Purchases of marketable
securities
$40,263,712
Stock-based compensation
$6,091,413
Prepaid expenses and
other current assets
-$1,179,004
Write-off of deferred
offering costs
$267,261
Depreciation and
amortization expense
$251,993
Non-cash interest
expense
$218,260
Net cash used in
operating activities
-$33,345,682
Canceled cashflow
$8,007,931
Net loss
-$33,846,661
Accrued expenses and
other liabilities
-$6,335,410
Net amortization of
premium on marketable...
$1,149,550
Accounts payable
-$21,992
Back
Back
Cash Flow
source: myfinsight.com
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)